Tag: Chondrosarcoma
Olutasidenib showed disease control in conventional chondrosarcoma
—
in OncologyPhase 1b/2 trial of olutasidenib in IDH1-mutated chondrosarcoma shows disease control without dose-limiting toxicities; 52% stable disease rate in recurrent/metastatic disease.
Combination therapy showed a temporary response in metastatic DDCS
—
in OncologyCase report demonstrates promising response to pembrolizumab and pazopanib combination therapy in metastatic dedifferentiated chondrosarcoma, highlighting emerging systemic treatment options.
Pediatric maxillary mesenchymal chondrosarcoma with HEY1::NCOA2 fusion
—
in PathologyCase report of mesenchymal chondrosarcoma in a 13-year-old with HEY1::NCOA2 fusion treated with multimodal therapy including sirolimus targeting mTOR pathway.
Three biomarkers were linked to angiogenesis and ISR in chondrosarcoma
—
Multi-omics analysis identifies HSPA8, LMNA, and SERPINH1 as angiogenesis and integrated stress response biomarkers in chondrosarcoma with therapeutic potential.
